Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: Findings from a phase III randomized, double-blind, multicenter trial in Japanese patients

Prostate Cancer and Prostatic Diseases

Volumn 10, Issue 2, 2007, Pages 194-201

  Usami, M ^a   Akaza, H ^b   Arai, Y ^c   Hirano, Y ^d   Kagawa, S ^e   Kanetake, H ^f   Naito, S ^g   Sumiyoshi, Y ^h   Takimoto, Y ⁱ   Terai, A ^j   Yoshida, H ^k   Ohashi, Y ^l  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

^e TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^f NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KYUSHU UNIVERSITY HOSPITAL   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

ⁱ NIHON UNIVERSITY   (Japan)

^j KURASHIKI CENTRAL HOSPITAL   (Japan)

^k SHOWA UNIVERSITY HOSPITAL   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HOT FLUSH; HUMAN; JAPAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT FAILURE;

AGED; ANILIDES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; NITRILES; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 34250008691     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500934     Document Type: Article

References (20)

1. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005; 12: 46-61.
2. Akaza H, Usami M, Hinotsu S, Ogawa O, Kagawa S, Kitamura T et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol 2004; 34: 329-336.
3. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int 2004; 93: 1177-1182.
4. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000; 355: 1491-1498.
5. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL et al. CJinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 1997; 50: 330-336.
6. Akaza H, Homma Y, Okada K, Yokoyama M, Usami M, Hirao Y et al. A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: Results of the 5-year follow-up. BJU Int 2003; 91: 33-36.
7. Kotake T, Usami M, Akaza H, Koiso K, Homma Y, Kawabe K et al. Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: A multicenter, randomized, controlled trial in Japan. Zoladex Study Group. Jpn J Clin Oncol 1999; 29: 562-570.
8. Kanetake H, Akaza H, Usami M. A phase III randomized trial of low dose flutamide compared with luteinizing hormone releasing agonist (LHRHa) vs LHRHa monotherapy for advanced prostate cancer. Japan Flutamide Study Cooperative Group. BJU Int 2004; 94: 58-59 (abstract).
9. Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 2004; 34: 20-28.
10. Kotake T, Akaza H, Usami M, Isaka S, Homma Y, Oishi K et al. Preliminary trial for clinical phase III study of Casodex (Bicalutamide ICI 176,334). J New Remedies Clinics 1999; 48: 1512-1533.
11. Kotake T, Usami M, Isaka S, Shimazaki J, Oishi K, Yoshida O et al. Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer. Hinyokika Kiyo 1996; 42: 143-153.
12. Kotake T, Usami M, Isaka S, Shimazaki J, Nakano E, Okuyama A et al. Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer. Hinyokika Kiyo 1996; 42: 157-168.
13. Japanese Urological Association and The Japanese Pathological Society. General Rule for Clinical and Pathological Studies on Prostate Cancer Kanehara: Tokyo, Japan, 1992, pp 100-106.
14. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43: 408-410.
15. Nieh PT. Withdrawal phenomenon with the antiandrogen casodex. J Urol 1995; 153: 1070-1073.
16. Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157: 1731-1735.
17. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H et al. European Association of Urology Guidelines on Prostate Cancer 2005 (online). http://www.uroweb.nl/files/uploaded_files/ 2005ProstateCancer.pdf.
18. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004; 171: 679-683.
19. Kaisary AV. Compliance with hormonal treatment for prostate cancer. Br J Hosp Med 1996; 55: 359-366.
20. Fourcade R-O, McLeod D. Tolerability of antiandrogens in the treatment of prostate cancer. Uro Oncol 2004; 4: 5-13.